Ulcerative Colitis and Biologic Therapy

Deep Dive

Ulcerative colitis is driven by dysregulated mucosal immunity, with cytokine networks and lymphocyte trafficking sustaining inflammation. Biolog... Ulcerative colitis is driven by dysregulated mucosal immunity, with cytokine networks and lymphocyte trafficking sustaining inflammation. Biologic therapy leverages monoclonal antibodies to interrupt these processes. Anti‑TNF agents such as infliximab, adalimumab, and golimumab neutralize TNF‑α, a master cytokine upstream of multiple inflammatory cascades. Across ACT, ULTRA, and PURSUIT trials, these agents induced clinical remission, achieved endoscopic improvement, and reduced corticosteroid dependence versus placebo. Vedolizumab, an α4β7 integrin antagonist, prevents gut‑homing of activated lymphocytes, offering gut‑selective immunosuppression. In GEMINI 1, it was effective for induction and maintenance, with a slower onset but favorable systemic safety. Ustekinumab, targeting the shared p40 subunit of IL‑12/23, and newer IL‑23 p19 inhibitors (mirikizumab, risankizumab) have expanded options, showing efficacy in both biologic‑naïve and biologic‑experienced patients (UNIFI; LUCENT; recent NEJM trials). In practice, biologics are introduced for moderate–severe UC, steroid‑refractory or ‑dependent disease, or early in high‑risk presentations under treat‑to‑target frameworks (STRIDE‑II). Choice reflects clinical priorities: need for rapid control (often anti‑TNF), systemic versus gut‑selective safety (vedolizumab), extraintestinal manifestations, and prior therapy exposure. Response assessment integrates patient reports, Mayo scores, biomarkers (CRP, fecal calprotectin), and endoscopic healing, with histologic improvement gaining prominence. Therapeutic drug monitoring is particularly useful in anti‑TNF secondary loss of response, where low trough levels or anti‑drug antibodies can guide optimization or class switching. Safety considerations are central. Baseline screening for tuberculosis and hepatitis B, ensuring up‑to‑date inactivated vaccinations, and counseling on avoidance of live vaccines during therapy help mitigate risks. Anti‑TNF therapy modestly increases serious infections and, with thiopurines, the risk of lymphoma and non‑melanoma skin cancer; vedolizumab’s gut selectivity confers a lower systemic infection risk. Ustekinumab and IL‑23 inhibitors have reassuring safety profiles to date. Infusion or injection reactions, immunogenicity, and rare events (demyelination with anti‑TNF, worsening heart failure) are monitored. Pregnancy data from registries are generally reassuring, especially for anti‑TNF, vedolizumab, and ustekinumab, with attention to infant vaccine timing after third‑trimester exposure. In older adults, infection vigilance is heightened. Overall, biologics substantially improve patient outcomes when paired with systematic monitoring and shared decision‑making.